CULLINAN THERAPEUTICS INC (CGEM)
US2300311063 - Common Stock
Interesting CGEM Put And Call Options For April 2025
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic...
Top movers in Friday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
What's going on in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top gainers and losers in today's session.
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic...
Interesting CGEM Put And Call Options For June 21st
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Let's have a look at the gap up and gap down stocks in today's session.
Which stocks are moving before the opening bell on Tuesday?
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical...
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to...
Commit To Purchase Cullinan Oncology At $7.50, Earn 6.2% Annualized Using Options
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the fourth quarter of 2023.
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cullinan Oncology (NASDAQ:CGEM) just reported results for the fourth quarter of...
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA...
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic...
Cullinan Oncology to Participate in Upcoming Investor Conferences
Commit To Purchase Cullinan Oncology At $7.50, Earn 13.8% Annualized Using Options
Cullinan Oncology (CGEM) Shares Cross Above 200 DMA
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on...
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic,...